Tags

Type your tag names separated by a space and hit enter

Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
Proteomics Clin Appl. 2014 Dec; 8(11-12):982-93.PC

Abstract

PURPOSE

Ovarian cancer is a devastating disease and biomarkers for its early diagnosis are urgently required. Serum may be a valuable source of biomarkers that may be revealed by proteomic profiling. Herein, complementary serum protein profiling strategies were employed for discovery of biomarkers that could discriminate cases of malignant and benign ovarian cancer.

EXPERIMENTAL DESIGN

Identically collected and processed serum samples from 22 cases of invasive epithelial ovarian cancer, 45 benign ovarian neoplasms, and 64 healthy volunteers were subjected to immunodepletion and protein equalization coupled to 2D-DIGE/MS and multidimensional fractionation coupled to SELDI-TOF profiling with MS/MS for protein identification. Selected candidates were verified by ELISA in samples from malignant (n = 70) and benign (n = 89) cases and combined marker panels tested against serum CA125.

RESULTS

Both profiling platforms were complementary in identifying biomarker candidates, four of which (A1AT, SLPI, APOA4, VDBP) significantly discriminated malignant from benign cases. However, no combination of markers was as good as CA125 for diagnostic accuracy. SLPI was further tested as an early marker using prediagnosis serum samples. While it rose in cases toward diagnosis, it did not discriminate prediagnosis cases from controls.

CONCLUSIONS AND CLINICAL RELEVANCE

The candidate biomarkers warrant further validation in independent sample sets.

Authors+Show Affiliations

EGA Institute for Women's Health, University College London, London, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25290619

Citation

Timms, John F., et al. "Discovery of Serum Biomarkers of Ovarian Cancer Using Complementary Proteomic Profiling Strategies." Proteomics. Clinical Applications, vol. 8, no. 11-12, 2014, pp. 982-93.
Timms JF, Arslan-Low E, Kabir M, et al. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Proteomics Clin Appl. 2014;8(11-12):982-93.
Timms, J. F., Arslan-Low, E., Kabir, M., Worthington, J., Camuzeaux, S., Sinclair, J., Szaub, J., Afrough, B., Podust, V. N., Fourkala, E. O., Cubizolles, M., Kronenberg, F., Fung, E. T., Gentry-Maharaj, A., Menon, U., & Jacobs, I. (2014). Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Proteomics. Clinical Applications, 8(11-12), 982-93. https://doi.org/10.1002/prca.201400063
Timms JF, et al. Discovery of Serum Biomarkers of Ovarian Cancer Using Complementary Proteomic Profiling Strategies. Proteomics Clin Appl. 2014;8(11-12):982-93. PubMed PMID: 25290619.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. AU - Timms,John F, AU - Arslan-Low,Elif, AU - Kabir,Musarat, AU - Worthington,Jenny, AU - Camuzeaux,Stephane, AU - Sinclair,John, AU - Szaub,Joanna, AU - Afrough,Babak, AU - Podust,Vladimir N, AU - Fourkala,Evangelia-Ourania, AU - Cubizolles,Myriam, AU - Kronenberg,Florian, AU - Fung,Eric T, AU - Gentry-Maharaj,Aleksandra, AU - Menon,Usha, AU - Jacobs,Ian, Y1 - 2014/11/10/ PY - 2014/06/17/received PY - 2014/08/05/revised PY - 2014/09/30/accepted PY - 2014/10/8/entrez PY - 2014/10/8/pubmed PY - 2015/9/1/medline KW - Diagnostic biomarkers KW - MS KW - Ovarian cancer KW - Serum profiling SP - 982 EP - 93 JF - Proteomics. Clinical applications JO - Proteomics Clin Appl VL - 8 IS - 11-12 N2 - PURPOSE: Ovarian cancer is a devastating disease and biomarkers for its early diagnosis are urgently required. Serum may be a valuable source of biomarkers that may be revealed by proteomic profiling. Herein, complementary serum protein profiling strategies were employed for discovery of biomarkers that could discriminate cases of malignant and benign ovarian cancer. EXPERIMENTAL DESIGN: Identically collected and processed serum samples from 22 cases of invasive epithelial ovarian cancer, 45 benign ovarian neoplasms, and 64 healthy volunteers were subjected to immunodepletion and protein equalization coupled to 2D-DIGE/MS and multidimensional fractionation coupled to SELDI-TOF profiling with MS/MS for protein identification. Selected candidates were verified by ELISA in samples from malignant (n = 70) and benign (n = 89) cases and combined marker panels tested against serum CA125. RESULTS: Both profiling platforms were complementary in identifying biomarker candidates, four of which (A1AT, SLPI, APOA4, VDBP) significantly discriminated malignant from benign cases. However, no combination of markers was as good as CA125 for diagnostic accuracy. SLPI was further tested as an early marker using prediagnosis serum samples. While it rose in cases toward diagnosis, it did not discriminate prediagnosis cases from controls. CONCLUSIONS AND CLINICAL RELEVANCE: The candidate biomarkers warrant further validation in independent sample sets. SN - 1862-8354 UR - https://www.unboundmedicine.com/medline/citation/25290619/Discovery_of_serum_biomarkers_of_ovarian_cancer_using_complementary_proteomic_profiling_strategies_ L2 - https://doi.org/10.1002/prca.201400063 DB - PRIME DP - Unbound Medicine ER -